NovAccel Established U.S. Subsidiary for Isotope Production
The Japanese accelerator developer aims to bolster North American supplies of medical-grade actinium-225.
Updated on Sept. 21, 2026 in Nuclear
Live Poll
Do you support companies prioritizing international expansion to improve the global supply of medical treatments?
NovAccel has incorporated a new U.S. subsidiary, NovAccel Isotopes Inc., to facilitate its expansion into the North American market. The company is developing proprietary compact superconducting accelerators to increase the global availability of the medical radioisotope actinium-225.
Why it matters
Medical radioisotopes are critical for targeted cancer therapies, and this move accelerates the company's ability to establish a localized supply chain. The expansion responds to growing clinical demand for isotopes used in radiopharmaceutical development.
NovAccel utilizes compact superconducting accelerator technology to produce medical isotopes. The company intends to leverage this hardware to streamline isotope output compared to conventional production methods.
The players
NovAccel, Inc.
A developer of compact superconducting accelerator technology headquartered in Tsuchiura City, Japan.
Arnaud Lesegretain
The CEO of NovAccel Isotopes Inc. and Chief Commercial and Business Officer of NovAccel, Inc.
Takashi Mizukami
The Director and Chief Strategy Officer of NovAccel, Inc. with a 20-year career in the resource industry.
The details
The company relies on a proprietary compact superconducting accelerator — a particle accelerator that uses magnets cooled to extreme temperatures to operate with lower electrical resistance — to produce medical radioisotopes. By scaling this technology, the firm aims to address the supply scarcity of actinium-225, a radioactive metal currently in high demand for experimental cancer treatments. The new U.S. entity will oversee business development and logistics to integrate these production capabilities into the North American medical supply chain.
Timeline
July 2026: NovAccel Isotopes Inc. was incorporated in Delaware.
September 21, 2026: The company announced the establishment of its U.S. subsidiary.
2027: Operations are scheduled to commence at the Hiroshima facility.
The Tech Race
This development follows established patterns in the international production pipeline for actinium-225, marking an attempt to decentralize manufacturing. The firm is positioning its superconducting accelerator technology to compete with traditional cyclotron-based isotope production methods.
This expansion primarily affects medical researchers and pharmaceutical firms in North America requiring reliable access to actinium-225 for cancer therapies. Healthcare providers and patients may see indirect benefits once the company successfully scales its supply chain and facility operations.
The takeaway
The move signifies an effort to move isotope production closer to the end-user market in the U.S. Watch for updates regarding the 2027 opening of the Hiroshima facility, which will serve as the technical benchmark for the company's intended U.S. manufacturing footprint.
Further reading
For more on the development of advanced isotope production, explore the Nuclear section.
More information
For inquiries regarding the company's production roadmap, visit the NovAccel public relations contact portal.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you support companies prioritizing international expansion to improve the global supply of medical treatments?
